Biotomo Technology Platform Biotomo trading as Biomimetics(Au) has developed a range of bone repair and
regeneration materials that have superior bioactivity and strength which can be successfully used in load
Natural bone consists of approximately 70% inorganic material that resembles synthetic
Hydroxyapatite (calcium phosphate) with interconnected pore structure of 100 - 500 micron
to allow vascularisation and bone growth.
BioTomo Pty Ltd utilizes a synthetic bone like material of 150 to 400 micron pore size with
appropriate interconnectivity and mechanical strength.
With a transformative innovation, biomaterials can be coated with bone-like carbonate apatite thin films using our unique nanotechnology. These materials can be coated onto surfaces of any size and shape.
This process preserves the larger interpores necessary for
successful osseo-integration. Increased surface area generated with this coating increases both the strength and bioactivity and
hence produces better and accelerated bonding to the natural bone, faster healing and reduced hospitalization.
Natural bone has osteoinductivity that allows new bone growth both internal and external structures. All biocompatible synthetic materials are
osteoconductive as scaffolds and allow only external surface reactivity and growth. Biomimetics’ biomaterials are all carbonate
hydroxyapatite material with osteoinductive properties similar to the natural bone that is not observed in any other synthetic material
currently available in the market place.
In addition this uniquely structured bone graft material with natural bone like chemistry and fine interconnected porous architecture
may be used for drug elution and dissolution in appropriate applications.
The company’s inventive technology platform and their advantages include:
Material Production Process
• HaP Product Range
• Putty and Gels
• Efficacy vs. current solutions
• Reduced number of procedures
•Reduced surgical interventions
• Minimise recovery time
• A range of ceramic and mixed oxides, and calcium phosphates
• High adhesive characteristics
of applied coating
• Enhanced bio-activity
• Wide usage potential in both medical
and non-medical applications
Bone Graft Material
• Long bone
• Provides load bearing capability
• Provides enhanced bio-activity
Slow drug release
• Dissolution rate controllable
calcium phosphate delivery systems
• Polymeric delivery systems
• Pharmaceutical delivery during implant
surgery by an innovative design
•Antibiotic ad bone repair and
regeneration drug delivery
Intellectual Property Status
The company has an extensive intellectual property portfolio covering its current product development activities.
The company core intellectual property is protected by patents accepted both in the United States and Australia and a European patent still pending. Biomimetics (Au) is currently expanding its intellectual property portfolio to incorporate additional divisional filings and further provisional patent applications.